文献速递药物相互作用药物不良反应与药物警戒

生理药代动力学模型研究COVID-19细胞因子风暴对CYP3A药物药代动力学的影响

Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.
PubMed 文献 · Clin Pharmacol Ther · 2021-09-22

该研究利用生理药代动力学(PBPK)模型模拟炎症对CYP3A代谢药物药代动力学的影响,模型基于HIV感染者洛匹那韦/利托那韦(LPV/r)临床数据开发,并经COVID-19患者数据验证。模拟显示COVID-19患者LPV暴露量较HIV感染者高两倍,利托那韦暴露相当,细胞因子风暴使咪达唑仑暴露增加40%。提示COVID-19患者CYP3A代谢改变,使用窄治疗指数药物尤其联用强CYP3A抑制剂时需谨慎。

要点

  • COVID-19细胞因子风暴可抑制CYP3A代谢,使咪达唑仑暴露增加40%。
  • COVID-19患者LPV暴露较HIV感染者高两倍,利托那韦暴露相当。
  • 窄治疗指数CYP3A底物联用强抑制剂时需警惕暴露升高。

核心结论

  • COVID-19患者细胞因子释放增加可改变CYP3A代谢,模拟显示咪达唑仑暴露增加40%。
  • 临床处方窄治疗指数药物尤其联用强CYP3A抑制剂时需谨慎。

研究设计与样本

  • 基于HIV感染者临床数据开发LPV/r的PBPK模型,用半机制抑制模型实现IL-6对CYPs的抑制,并经COVID-19患者LPV/r治疗数据验证。
  • 验证后模型模拟不同临床观察IL-6水平对LPV/r和咪达唑仑暴露的影响。

主要发现

  • 临床观察的HIV感染者和COVID-19患者LPV/r浓度均落在模拟结果95%置信区间内,显示模型预测能力。
  • 模拟显示COVID-19患者LPV暴露较HIV感染者高两倍,利托那韦暴露预测相当。
  • COVID-19下不同IL-6水平对LPV/r药代动力学仅有边缘影响。
  • 模拟显示细胞因子风暴使CYP3A模型底物咪达唑仑暴露增加40%。

临床怎么用

  • COVID-19患者使用窄治疗指数CYP3A底物时,尤其联用强CYP3A抑制剂,应警惕暴露升高并加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with coronavirus disease 2019 (COVID-19) may experience a cytokine storm with elevated interleukin-6 (IL-6) levels in response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). IL-6 suppresses hepatic enzymes, including CYP3A; however, the effect on drug exposure and drug-drug interaction magnitudes of the cytokine storm and resulting elevated IL-6 levels have not been characterized in patients with COVID-19. We used physiologically-based pharmacokinetic (PBPK) modeling to simulate the effect of inflammation on the pharmacokinetics of CYP3A metabolized drugs. A PBPK model was developed for lopinavir boosted with ritonavir (LPV/r), using clinically observed data from people living with HIV (PLWH). The inhibition of CYPs by IL-6 was implemented by a semimechanistic suppression model and verified against clinical data from patients with COVID-19, treated with LPV/r. Subsequently, the verified model was used to simulate the effect of various clinically observed IL-6 levels on the exposure of LPV/r and midazolam, a CYP3A model drug. Clinically observed LPV/r concentrations in PLWH and patients with COVID-19 were predicted within the 95% confidence interval of the simulation results, demonstrating its predictive capability. Simulations indicated a twofold higher LPV exposure in patients with COVID-19 compared with PLWH, whereas ritonavir exposure was predicted to be comparable. Varying IL-6 levels under COVID-19 had only a marginal effect on LPV/r pharmacokinetics according to our model. Simulations showed that a cytokine storm increased the exposure of the CYP3A paradigm substrate midazolam by 40%. Our simulations suggest that CYP3A metabolism is altered in patients with COVID-19 having increased cytokine release. Caution is required when prescribing narrow therapeutic index drugs particularly in the presence of strong CYP3A inhibitors.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stader F, Battegay M, Sendi P, et al. Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. Clin Pharmacol Ther. 2021. PMID: 34496043. doi:10.1002/cpt.2402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。